Sickle cell disease trials in Canada

In Canada 14 Also abroad 204

14 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype
Where
Montreal, Toronto
Age
16 years to 50 years
People
65
Run by
Biossil Inc.
See details and how to joinNCT07282210
Phase 4Enrolling by invitation
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
Where
Hamilton, Toronto
Age
18 years and over
People
55 worldwide
Run by
Agios Pharmaceuticals, Inc.
See details and how to joinNCT05777993 · EU 2026-526243-35-00
Phase 2Taking people
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Where
Toronto
Age
6 months to 18 years
People
95 worldwide
Run by
Forma Therapeutics, Inc.
See details and how to joinNCT06198712 · EU 2024-519881-32-00
Phase 3Taking people
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Where
Montreal, Toronto, Vancouver
Age
2 years and over
People
480 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00
Phase 3Taking people
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Where
Calgary, Edmonton, London, Montreal, Scarborough Village, Toronto, Vancouver
Age
12 years and over
People
510 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT06612268 · EU 2023-509175-16-00
Phase 2/3Taking people
Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia
Where
Montreal
Age
6 months to 18 years
People
29
Run by
Yves Pastore
See details and how to joinNCT06761560
Phase 1/2Taking people
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Where
Vancouver
Age
18 years and over
People
224 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06481306 · EU 2023-510283-12-00
Phase 3Enrolling by invitation
A Long-term Follow-up Study in Participants Who Received CTX001
Where
Toronto, Vancouver
Age
2 years to 64 years
People
160 worldwide
Run by
Vertex Pharmaceuticals Incorporated
See details and how to joinNCT04208529 · EU 2024-512654-19-00
No phaseTaking people
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
Where
Calgary, Montreal, Toronto, Vancouver, Winnipeg
Age
3 years to 20 years
People
480 worldwide
Run by
University of Rochester
See details and how to joinNCT06941389
Phase 2Taking people
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
Where
Calgary
Age
1 year to 19 years
People
12
Run by
University of Calgary
See details and how to joinNCT03214354
Phase 2Taking people
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
Where
Calgary, Toronto
Age
2 years to 25 years
People
100 worldwide
Run by
Robert Nickel
See details and how to joinNCT03587272
Phase 1/2Enrolling by invitation
The BENeFiTS Trial in Beta Thalassemia Intermedia
Where
Toronto
Age
18 years and over
People
36 worldwide
Run by
Phoenicia BioScience
See details and how to joinNCT04432623
No phaseEnrolling by invitation
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
Where
Ottawa, Toronto
Age
12 years to 50 years
People
54 worldwide
Run by
Editas Medicine, Inc.
See details and how to joinNCT06363760
No phaseEnrolling by invitation
SCRIPT: Sickle Cell Risk in Pregnancy Tool
Where
Montreal, Vancouver
Age
16 years to 60 years
People
1,000 worldwide
Run by
Mount Sinai Hospital, Canada
See details and how to joinNCT06529042